Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety

Frederick Cohen(Allogene Therapeutics (United States)), Ryan T. Cirz(Scripps Research Institute), Kevin M. Krause(Allogene Therapeutics (United States)), Paola Dozzo(Allogene Therapeutics (United States)), Darin J. Hildebrandt(Allogene Therapeutics (United States)), Zahra Assar(Cayman Chemical (United States)), Andrei W. Konradi(Peninsula Library System), Adrian M. Jubb(Allogene Therapeutics (United States)), Kristin M. Joly(ARCA Biopharma (United States)), Vincent Nieto(Allogene Therapeutics (United States)), J. Michael Boggs(Allogene Therapeutics (United States)), Anton Shakhmin(Nanosyn (United States)), Taylor A. Choi(Allogene Therapeutics (United States)), Alex D. Sun(Nanosyn (United States)), Melissa C. Holt(Cayman Chemical (United States)), Timothy R. Kane(Allogene Therapeutics (United States)), Timothy Machajewski(Allogene Therapeutics (United States)), Logan D. Andrews(Allogene Therapeutics (United States)), Martin S. Linsell(Allogene Therapeutics (United States)), Kenneth B. Wlasichuk(Allogene Therapeutics (United States)), Adam J. Stein(Cayman Chemical (United States)), Thu Phan(Nanosyn (United States)), James B. Aggen(Allogene Therapeutics (United States)), Ashton N. Easterday(Allogene Therapeutics (United States)), Serguei Sviridov(Nanosyn (United States)), Heinz E. Moser(Allogene Therapeutics (United States)), Craig F. Plato(ARCA Biopharma (United States)), Julie D. Seroogy(Allogene Therapeutics (United States)), О. В. Мирошникова(Nanosyn (United States)), Xiaoming Zhou(Pharmaron (United Kingdom)), Hai Zhu(Nanosyn (United States)), Zhan Wang(Qinghai University), Zeeshan Kamal(Nanosyn (United States)), Alisa W. Serio(Allogene Therapeutics (United States)), Wen Yang(Nanosyn (United States)), Cat M. Haglund(Allogene Therapeutics (United States))
ChemMedChem
July 8, 2019
Cited by 76


Related Papers